SCCLG-ALL-2016方案治疗初诊CD20抗原阳性儿童B-ALL的临床特点及生存分析  

Clinical characteristics and survival analysis of SCCLG-ALL-2016 regimen for B-ALL in newly diagnosed CD20 antigen-positive children

作　　者：丘家鹏 田川 叶中绿 蓝翔 刘丽丽 QIU Jia-peng;TIAN Chuan;YE Zhong-lyu(Children's Medical Center,Affiliated Hospital of Guangdong Medical University,Zhanjiang Guangdong 524000,China)

机构地区：[1]广东医科大学附属医院儿童医学中心,广东湛江524000

出　　处：《临床和实验医学杂志》2024年第18期1970-1974,共5页Journal of Clinical and Experimental Medicine

基　　金：广东省科技计划项目(编号:2023B01174)。

摘　　要：目的 探讨华南地区儿童急性淋巴细胞白血病(ALL)治疗协作组2016治疗方案(SCCLG-ALL-2016)对儿童B细胞起源ALL(B-ALL)中CD20抗原表达与一般临床特点以及预后之间的关系。方法 回顾性分析2016年10月至2023年12月期间在广东医科大学附属医院接受治疗的113例初诊B-ALL患儿的临床特点以及生存情况,分析其基本资料与临床特征、染色体核型、融合基因、临床危险度、骨髓缓解、复发情况及生存曲线。结果 113例初诊B-ALL患儿CD20阳性表达率23.01%;CD20阳性表达与性别、脾脏增大、初诊血小板计数以及融合基因方面存在显著统计学意义(P<0.05)。CD20抗原阳性组与CD20抗原阴性组患儿在初诊年龄、初诊白细胞计数、染色体核型、第15、33天骨髓残留情况以及复发方面的差异均无统计学意义(P>0.05)。生存曲线分析结果显示,CD20抗原阳性组患儿的3年无事件生存(EFS)率为(75.3±10.2)%,CD20抗原阴性组患儿的3年EFS率为(85.2±4.3)%;两组间比较差异无统计学意义(P>0.05)。CD20抗原阳性组患儿的总生存期(OS)率为(82.8±7.9)%,而CD20抗原阴性组患儿的OS率为(90.4±3.2)%,两组间比较差异无统计学意义(P>0.05)。结论 在儿童B-ALL中,CD20抗原的表达与性别、脾脏情况、初诊血小板计数以及融合基因表达相关,但与其他一般临床特点和预后无关,CD20抗原不是B-ALL患儿预后的影响因素,脾脏是否增大、初诊白细胞计数、危险度及融合基因是影响B-ALL患儿预后的独立因素。Objective To investigate the relationship between CD20 antigen expression,general clinical features and prognosis of pediatric B-line acute lymphoblastic leukemia(ALL)treated with 2016 program of the South China children's acute lymphoblastic leukemia treatment cooperation group(SCCLG-ALL-2016 regimen).Methods The clinical characteristics and survival of 113 children with newly diagnosed B-ALL who were treated in Affiliated Hospital of Guangdong Medical University from October 2016 to December 2023 were retrospectively analyzed.The basic data and clinical characteristics,chromosome karyotype,fusion gene,clinical risk,bone marrow remission,recurrence and survival curve of them were analyzed.Results CD20 antigen positive expression rate was 23.01%in 113 newly diagnosed children with B-ALL.CD20 antigen positive expression was statistically significant with gender,spleen enlargement,platelet count at first diagnosis and fusion gene(P<0.05).There were no statistically significant differences in age at first diagnosis,white blood cell count at first diagnosis,chromosome karyotype,bone marrow residue at day 15 and day 33,and recurrence between the CD20 antigen positive group and the CD20 antigen negative group.Survival curve analysis showed that,the 3-year event-free survival(EFS)rate was(75.3±10.2)%in the CD20 antigen positive group and(85.2±4.3)%in the CD20 antigen negative group;there was no statistically significant difference between the two groups(P>0.05).The overall survival(OS)rate of the CD20 antigen positive group was(82.8±7.9)%,while that of the CD20 antigen negative group was(90.4±3.2)%;there was no statistically significant difference between the two groups(P>0.05).Conclusion In children with B-ALL,the expression of CD20 antigen is correlated with sex,spleen condition,platelet count at first diagnosis and fusion gene expression,but not with other general clinical features and prognosis.CD20 antigen is not a prognostic factor,and spleen enlargement,white blood cell count at first diagnosis,risk and fusio

关 键 词：儿童 CD20抗原 急性B淋巴细胞白血病 临床特点 生存分析 

分 类 号：R733.71[医药卫生—肿瘤]